德琪医药-B(06996)午前股价上涨16.35%,现报6.19港元,成交额5083.529万港元。
8月11日,CDE网站显示,6款药物拟纳入突破性疗法,其中包括ATG-022。据悉,ATG-022是德琪医药自主研发的Claudin 18.2抗体偶联药物。此前,公司在ASCO GI 2025大会上公布了ATG-022的最新临床数据:在CLDN18.2中高表达(IHC 2+ ≥ 20%)患者中,客观缓解率(ORR)为42.9%,疾病控制率(DCR)为95.2%;在CLDN18.2低表达(IHC 2+ < 20%)患者中,ORR为30.0%,DCR为50.0%。公司将在2025年10月的ESMO年会上公布ATG-022的最新研究数据。
责任编辑:卢昱君
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.